Aims & Objective: Transcatheter ventricular septal defect (VSD) device closure is usually performed using the antegrade approach [1-3]. A few case series of a retrograde technique using the Amplatzer duct occluder (ADO) II device have been reported [4, 5] . We aimed to assess the feasibility and safety of a retrograde closure technique using an ADO I like device, which is used for the closure of patent ductus arteriosus (PDA).
Introduction
Transcatheter ventricular septal defect (VSD) device closure is a commonly performed procedure to close perimembranous VSDs (PMVSD), especially those that are moderately restrictive without severe pulmonary artery hypertension. Transcatheter clo-Transcatheter Trans-aortic Retrograde Approach for the Closure of Perimembranous Ventricular Septal Defects using Cocoon [Amplatzer Duct Occluder I Like] Device -An Initial Experience from a Single Centre sure is preferred wherever possible in view of shorter hospital stay, easier recovery, cost-effectiveness, and cosmetic reasons.
The procedure is commonly done by an antegrade technique via the right ventricle, using an arterio-venous loop. A trans-aortic retrograde technique using Amplatzer membranous or duct occluder (ADO) II has also been described [1] . Though procedure time and radiation exposure is less with the retrograde technique it has certain limitations. It cannot be used in patients with perimembranous VSDs with aortic rim less than 3 mm [1] . Secondly, the ADO II device is expensive and its routine use, especially in resource-limited settings may not be cost effective. We therefore aimed to assess the feasibility and safety of a retrograde technique for VSD device closure using an indigenously manufactured low cost ADO I like device. We further aimed to demonstrate that this approach could be used irrespective of the adequacy of the aortic rim.
Methods

Patient population
This series included eight consecutive patients with perimembranous VSDs who underwent percutaneous VSD device closure by the trans-aortic retro-grade approach using an ADO I like device at a single tertiary care center in South India over a three year period (2015-2018). The hospital institutional review board and ethics committee approved the study. All patients gave informed consent. VSD closure was performed as per standard indications in symptomatic patients, with significant shunt as evidenced by standard clinical (mid-diastolic flow murmur), electrocardiographic (left atrial enlargement, left ventricular hypertrophy) or imaging criteria (Qp/Qs > 1.5 by echocardiography or cardiac catheterization. Perimembranous VSDs with aortic rim less than 5 mm were also included.
Cases that had significant aortic valve prolapse with aortic insufficiency, defect size >10mm, and severe pulmonary hypertension were excluded. The patients underwent clinical and echocardiographic follow-up one week after the procedure and then once every three months for one year.
Description of technique
Infective endocarditis prophylaxis was administered in all cases. Calculation of VSD diameter and its relation to the aortic valve was determined using trans-thoracic echocardiography (TTE) (Figure 2A & B) only without performing ventriculography. Following femoral arterial access with a 7 French sheath, the defect was crossed from the left ventricle using an exchangeable 0.035-inch angulated floppy hydrophilic guide wire (Radio focus, Terumo cooperation, Tokyo, Japan) through either a Judkins right or Amplatz right diagnostic coronary artery catheter (Medtronic, Minnesota, USA) ( Figure 3A ). The catheter was then advanced over the wire into either the pulmonary artery (PA) or superior vena cava (SVC). The hydrophilic wire exchanged for an Amplatz extra-stiff soft tip wire (Cook Medical Inc. Bloomington, USA). A 7-8 Fr. delivery sheath along with its dilator which used for the closure of patent ductus arteriosus (PDA), was advanced through the defect into the right ventricle (RV) over the Amplatz stiff wire. The sheath was advanced slowly towards the apex of the RV while withdrawing the dilator and was positioned 3-5 cm beyond the defect ( Figure 3B ). A device 1 to 2 mm larger than the measured VSD diameter was pre-loaded on a delivery cable and advanced to the tip of the delivery sheath. The entire system was then withdrawn sheath alone was then further pulled back to successively deploy the waist and finally the LV disc of the device. Check angiography was performed through the side arm of the delivery sheath by hand injection to confirm device position. TTE was also performed to visualize the placement of the device on the defect, function of the tricuspid, mitral, and aortic valves and back towards the VSD under fluoroscopic and transthoracic echocardiographic guidance ( Figure 3C ). The RV disc was exteriorized 1-2 cm distal to the defect while avoiding entrapment of the chordal elements of the tricuspid valve. The whole system was then further withdrawn till the RV disc was firmly seated on the RV aspect of the defect. Keeping it steady, the fect size was 6.6 mm (4.5 -8.6 mm), with a median aortic rim of 3.4 mm (range 2-5 mm). Aortic rims were < 5 mm in all cases except one. Median Qp/Qs and right ventricular systolic pressure were 1.8 (range: 1.6-2.1) and 41.3 mm Hg (range: 33-50 mm Hg) respectively. All patients underwent successful VSD device closure using the retrograde approach. The procedural details are presented in Table 2 . Median fluoroscopy and procedure times were 13.3 (10.6-15.7) and 23.5 (18.2-27.2) minutes respectively. Device sizes ranged from 4/6 to 10/12 mm and 10/12 mm was the maximum size used in this series. One patient had minimal residual shunt and the rest had no residual shunt acutely after device deployment. There was no impingement on either the tricuspid or aortic valves from the device with no instances of valvular regurgitation. Additionally no patient developed hemolytic anemia or jaundice in the post procedure period.
All Patients were discharged 24 hours after the procedure. No acute device dislodgements or AV block were encountered. No other acute complications occurred in the immediate post procedural period and all patients made an uneventful recovery.
Patients were followed for a median of 18 (12 -28) months during which all stayed asymptomatic with good effort tolerance. There was no residual shunt or late dislodgement of the device by echocardiography in any case. No patient developed delayed conduction system disturbance or AV block. any residual shunt prior to finally releasing the device ( Figure 3D ) All patients were administered dual antiplatelet therapy with acetylsalicylic acid 3-5 mg/kg/ day and clopidogrel 1-2 mg/Kg/day for the duration of six months post device closure.
Close follow-up was done on 10 th day post-discharge using Clinical examination and TTE. (Figure 4 ) Thereafter, patients were followed every 3 months for the period of one year or earlier if patients develop any symptoms in the form of breathlessness, giddiness or syncope. After one year, follow -ups were advised either symptom driven or every 4 to 6 months.
Occluder devices
We used the 'Cocoon' PDA device [manufactured by Vascular lnnvovations Co. Ltd. Nonthaburi,Thailand & marketed by Vascular Concepts, Bangalore, India] which is very similar to the Amplatzer duct occluder I (ADO I) in terms of design and implantation technique (Figure 1 ).
Results
Between June 2015 and January 2018, eight patients underwent VSD device closure using the technique and device described above. Demographic and clinical characteristics of the cases are summarized in Table 1 . The median age was 17.1 years (range 5-32 years) with 3 males and 5 females. All patients had perimembranous ventricular septal defects. Mean de- [5] . After the introduction of the Amplatzer device in 1999, the closure of muscular VSDs using the Amplatzer muscular VSD occluder (MVSDO) was published in 2002. Though transcatheter closure of muscular VSDs, was a better option than surgical closure, significant incidence of atrioventricular block varying from to 3-20% was seen [6] . Despite the development of the dedicated Amplatzer Perimembranous VSD Occluder (PMVSDO) for the closure of perimembranous VSDs, a occurrence of AVB was a concern [7, 8]. The tranvenous antegrade technique had more radiation exposure and cumbersome procedure. The trans-arterial retrograde technique, initially using the Amplatzer symmetrical muscular VSD device [9, 10] and subsequently the ADO II device to minimize the risk of atrioventricular block (AVB) and tricuspid valve en-
Discussion
To the best of our knowledge, this is the first reported case series in literature using a combination of retrograde VSD device closure technique and ADO I like device. Though the retrograde approach has been described before using the ADO II device [1] [2] [3] , there are some limitations in cases with aortic rim less than 5 mm and more procedure time and radiation exposure. The ADO II device is also relatively expensive to use in resource limited contexts such as the Indian setting. Koneti et al. reported the fluoroscopy time of 14 minutes in their series where trans-arterial retrograde technique was done using an ADO II device. [4] In our series, fluroscopy time was 13.3 minutes. As our experience grew, there was further reduction of fluroscopy time from 15.7 to 10.6 minutes.
In this series, we used an ADO I like device -'Cocoon Device" [manufactured by Vascular lnnvovations Co. Ltd. Nonthaburi, Thailand & marketed by Vascular Concepts, Bangalore, India] for the first time using a trans-aortic retrograde technique. We were able to use this device in all cases irrespective of aortic rim size. Another advantage of using ADO I like device is that it has a low profile with small retention disc on the right ventricular side and no disc on the left ventricular side which lowers the risk of encroachment on vital cardiac structures. We also used 7/8 Fr term data with larger number of patients will be needed to draw more definitive conclusions. In this initial series, we did not attempt to close larger defect sizes, patients < 3 years of age or those with severe reversible pulmonary artery hypertension; hence our findings may not be applicable to these subsets. However the data from this early study appears promising and should prompt further evaluation in a wider spectrum of patients.
Conclusion
In this initial experience, retrograde trans-arterial closure of VSD using an ADO-I like device appears feasible and relatively more cost-effective. It can help further reduce radiation exposure and can be potentially applied in all cases even with deficient aortic rim. Further studies are required to document its efficacy, safety and long-term results in a larger number of patients.
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trapment with possible tricuspid regurgitation during follow-up, got more attention [2, 4] . The advantage of this approach is that it is also useful in patients with venous anomalies, such as interrupted inferior vena cava [11] . It has been reported that the trans-aortic approach causes a lower incidence of AVB than the antegrade approach [9, 12] .
ADO I or its chinese counterparts were used in a few case reports by antegrade approach for the closure of residual post-surgical VSDs [13, 14] and for the closure of multi-perforated perimembranous VSD with aneurysm [15] . Recently, Nguyen et al. published a multicenter case series of antegrade transvenous closure of PMVSD using ADO I with 95% success rate and with complications in 1.7% of cases. They had embolization of device in 1% of cases and AVB in 0.7% of cases [16] .
The risk of embolization is inherant complication of any device closure but in our case, the non-presence of disc on the LV side doesnot increase it further. Basically, device sits there as it fits snuggly and the LV pressure cannot push the device as the LV contracts circumferentially in systole by rotation and torsion [17] . In our small case series, there were no embolization and also no evidence of tricuspid regurgitation. One case had minimal residual shunt which resolved completely at the 1-month follow-up.
Study limitations
Our study had a small number of cases, and should be considered an initial feasibility study. More long-
